KR102499191B1 - Cd20 면역요법을 위한 조성물 및 방법 - Google Patents

Cd20 면역요법을 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102499191B1
KR102499191B1 KR1020227005550A KR20227005550A KR102499191B1 KR 102499191 B1 KR102499191 B1 KR 102499191B1 KR 1020227005550 A KR1020227005550 A KR 1020227005550A KR 20227005550 A KR20227005550 A KR 20227005550A KR 102499191 B1 KR102499191 B1 KR 102499191B1
Authority
KR
South Korea
Prior art keywords
cells
cell
lymphoma
seq
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227005550A
Other languages
English (en)
Korean (ko)
Other versions
KR20220030307A (ko
Inventor
올리버 프레스
브라이언 틸
Original Assignee
프레드 허친슨 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프레드 허친슨 캔서 센터 filed Critical 프레드 허친슨 캔서 센터
Publication of KR20220030307A publication Critical patent/KR20220030307A/ko
Application granted granted Critical
Publication of KR102499191B1 publication Critical patent/KR102499191B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020227005550A 2016-03-18 2017-03-17 Cd20 면역요법을 위한 조성물 및 방법 Active KR102499191B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662310541P 2016-03-18 2016-03-18
US62/310,541 2016-03-18
US201662320327P 2016-04-08 2016-04-08
US62/320,327 2016-04-08
KR1020187026926A KR102366611B1 (ko) 2016-03-18 2017-03-17 Cd20 면역요법을 위한 조성물 및 방법
PCT/US2017/023098 WO2017161353A1 (en) 2016-03-18 2017-03-17 Compositions and methods for cd20 immunotherapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026926A Division KR102366611B1 (ko) 2016-03-18 2017-03-17 Cd20 면역요법을 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20220030307A KR20220030307A (ko) 2022-03-10
KR102499191B1 true KR102499191B1 (ko) 2023-02-13

Family

ID=58448653

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227005550A Active KR102499191B1 (ko) 2016-03-18 2017-03-17 Cd20 면역요법을 위한 조성물 및 방법
KR1020187026926A Active KR102366611B1 (ko) 2016-03-18 2017-03-17 Cd20 면역요법을 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187026926A Active KR102366611B1 (ko) 2016-03-18 2017-03-17 Cd20 면역요법을 위한 조성물 및 방법

Country Status (14)

Country Link
US (2) US10875927B2 (enExample)
EP (2) EP3939994A3 (enExample)
JP (2) JP7065782B2 (enExample)
KR (2) KR102499191B1 (enExample)
CN (1) CN108884144B (enExample)
AU (1) AU2017235657B2 (enExample)
BR (1) BR112018067977A8 (enExample)
CA (1) CA3015369A1 (enExample)
DK (1) DK3430038T3 (enExample)
ES (1) ES2893840T3 (enExample)
IL (1) IL261316B2 (enExample)
MX (1) MX2018010415A (enExample)
NZ (1) NZ744913A (enExample)
WO (1) WO2017161353A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
CN105985444B (zh) * 2015-02-05 2024-02-13 博生吉安科细胞技术有限公司 一种嵌合抗原受体、以及快速构建嵌合抗原受体的方法及应用
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
JP7357626B2 (ja) 2017-11-01 2023-10-06 ジュノー セラピューティクス インコーポレイテッド 操作された細胞の治療用組成物を生成するためのプロセス
AU2018379091A1 (en) 2017-12-08 2020-06-25 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
AU2019216269B2 (en) * 2018-01-30 2025-05-01 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen
CN112368021B (zh) 2018-06-14 2025-02-21 2赛文缇生物公司 Cd79a嵌合抗原受体
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
CN109293781A (zh) * 2018-09-12 2019-02-01 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、cd19-cd20双靶向性的t细胞及其应用
CN112840026B (zh) * 2018-10-18 2025-01-14 施能康公司 抑制tigit基因表达的组合物和方法
KR20250116790A (ko) 2018-12-12 2025-08-01 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
WO2020180648A1 (en) * 2019-03-01 2020-09-10 Gritstone Oncology, Inc. Selection of t cell receptors
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
MX2021015495A (es) * 2019-06-14 2022-04-18 2Seventy Bio Inc Composiciones y métodos para tratar cáncer.
AU2020315213A1 (en) * 2019-07-17 2022-02-03 National University Of Singapore Functional binders synthesized and secreted by immune cells
US20220411479A1 (en) * 2019-10-30 2022-12-29 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
CN111944062B (zh) * 2019-12-09 2023-11-07 深圳市体内生物医药科技有限公司 一种识别Fc片段的嵌合抗原受体及其应用
KR20220149606A (ko) * 2020-03-02 2022-11-08 더 리전츠 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 키메라 항원 수용체 및 관련 방법 및 조성물
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
WO2021231959A1 (en) * 2020-05-15 2021-11-18 Precision Biosciences, Inc. Methods for immunotherapy
WO2021231954A1 (en) * 2020-05-15 2021-11-18 Precision Biosciences, Inc. Methods for immunotherapy
CN114774364B (zh) * 2022-04-26 2024-04-26 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
CN117343176A (zh) * 2022-07-04 2024-01-05 上海优卡迪生物医药科技有限公司 人源化的结合cd20的抗体或cd20抗原结合片段及应用
WO2024097313A1 (en) * 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Methods for producing t cell therapy products
PE20260290A1 (es) 2023-03-31 2026-02-10 Abelzeta Inc Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods
WO2026073918A1 (en) * 2024-10-02 2026-04-09 Galapagos Nv Novel anti-cd20 binding domains and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023573A2 (en) * 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
EP1891113A2 (en) * 2005-06-02 2008-02-27 AstraZeneca AB Antibodies directed to cd20 and uses thereof
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
KR20100102172A (ko) 2007-12-21 2010-09-20 제넨테크, 인크. 리툭시마브-난치성 류마티스성 관절염 환자의 요법
KR101319499B1 (ko) 2008-02-22 2013-10-17 엘지디스플레이 주식회사 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) * 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
US20140004037A1 (en) 2012-01-19 2014-01-02 Therapeutic Proteins, Inc. Stabilization of the anti-cd20 antibody rituximab
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
KR102185175B1 (ko) 2012-11-02 2020-12-02 티지 쎄라퓨틱스, 인코포레이티드 항cd20 항체와 pi3 키나아제 선택적 억제제의 조합물
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2015042807A1 (zh) * 2013-09-25 2015-04-02 北京安保康生物医药科技有限公司 抗cd20的全人源单克隆抗体及其应用
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
JP6831777B2 (ja) * 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
CN105330750B (zh) * 2015-11-20 2019-02-01 上海细胞治疗研究院 一种快速中止car-t细胞杀伤作用的分子刹车及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023573A2 (en) * 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Immunology research, Vol. 4, No. 6, pp. 509-519 (2016.04.21.)
PLOS ONE, Vol. 8, No. 12, p. e82742 (2013.12.17.)

Also Published As

Publication number Publication date
BR112018067977A2 (pt) 2019-02-05
KR20180127348A (ko) 2018-11-28
IL261316B1 (en) 2024-01-01
AU2017235657A1 (en) 2018-09-06
JP2019515652A (ja) 2019-06-13
MX2018010415A (es) 2018-11-29
IL261316A (en) 2018-10-31
NZ744913A (en) 2025-09-26
CN108884144B (zh) 2023-03-14
KR102366611B1 (ko) 2022-02-23
EP3939994A3 (en) 2022-04-27
US20190106501A1 (en) 2019-04-11
RU2018134300A (ru) 2020-04-20
WO2017161353A1 (en) 2017-09-21
US10875927B2 (en) 2020-12-29
KR20220030307A (ko) 2022-03-10
JP2022002550A (ja) 2022-01-11
CA3015369A1 (en) 2017-09-21
EP3430038B1 (en) 2021-06-16
IL261316B2 (en) 2024-05-01
EP3430038A1 (en) 2019-01-23
BR112018067977A8 (pt) 2023-04-11
RU2018134300A3 (enExample) 2020-07-15
US20210147569A1 (en) 2021-05-20
JP7065782B2 (ja) 2022-05-12
DK3430038T3 (da) 2021-09-13
ES2893840T3 (es) 2022-02-10
CN108884144A (zh) 2018-11-23
AU2017235657B2 (en) 2022-07-21
EP3939994A2 (en) 2022-01-19
JP7397840B2 (ja) 2023-12-13
US11834511B2 (en) 2023-12-05

Similar Documents

Publication Publication Date Title
KR102366611B1 (ko) Cd20 면역요법을 위한 조성물 및 방법
KR102723896B1 (ko) 항클라우딘 18a2의 항체 및 이의 응용
JP6175590B1 (ja) 癌の治療に用いるための細胞傷害誘導治療剤
US12060394B2 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
KR102357004B1 (ko) 입양 세포 면역요법의 효능을 강화하기 위한 조성물 및 방법
RU2711975C2 (ru) Лечение рака с помощью гуманизированного анти-cd19 химерного антигенного рецептора
US9745368B2 (en) Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP2019536437A (ja) Ｈｐｖ特異的結合分子
KR20180134385A (ko) 선택적 단백질 발현을 위한 조성물 및 방법
CN113366017B (zh) 结合hla-dr的嵌合抗原受体和car-t细胞
WO2022012681A1 (en) Multispecific chimeric antigen receptors and uses thereof
KR20240099161A (ko) Bcma를 표적화하는 조성물 및 이의 사용 방법
IL297916A (en) Compositions and methods for tcr reprogramming using CD70-specific fusion proteins
RU2782699C2 (ru) Композиции и способы иммунотерапии против cd20
HK40067523A (en) Compositions and methods for cd20 immunotherapy
HK40052974B (en) Chimeric antigen receptor binding to hla-dr, and car-t cell
HK40003185B (en) Compositions and methods for cd20 immunotherapy
CA2955386A1 (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220218

Application number text: 1020187026926

Filing date: 20180917

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220321

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220401

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20221107

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20221125

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230208

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230208

End annual number: 3

Start annual number: 1

PG1601 Publication of registration